These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17318473)

  • 1. [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].
    Wittke S; Schiffer E; Bauer HW
    Urologe A; 2007 Jul; 46(7):733-9. PubMed ID: 17318473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive modeling in proteomics-based disease detection.
    Pham TD
    Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():3308-11. PubMed ID: 18002703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of muscle-invasive bladder cancer using urinary proteomics.
    Schiffer E; Vlahou A; Petrolekas A; Stravodimos K; Tauber R; Geschwend JE; Neuhaus J; Stolzenburg JU; Conaway MR; Mischak H; Theodorescu D
    Clin Cancer Res; 2009 Aug; 15(15):4935-43. PubMed ID: 19602546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of Raman spectroscopy to provide an estimation of the gross biochemistry associated with urological pathologies.
    Stone N; Hart Prieto MC; Crow P; Uff J; Ritchie AW
    Anal Bioanal Chem; 2007 Mar; 387(5):1657-68. PubMed ID: 17123068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.
    Barboro P; Rubagotti A; Orecchia P; Spina B; Truini M; Repaci E; Carmignani G; Romagnoli A; Introini C; Boccardo F; Carnemolla B; Balbi C
    Cell Oncol; 2008; 30(1):13-26. PubMed ID: 18219107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic studies in urological malignancies.
    Ferguson RE; Selby PJ; Banks RE
    Contrib Nephrol; 2004; 141():257-79. PubMed ID: 14650238
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany.
    Schiffer E; Bick C; Grizelj B; Pietzker S; Schöfer W
    Int J Urol; 2012 Feb; 19(2):118-25. PubMed ID: 22103570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-dimensional capillary electrophoresis and chromatography for proteomic analysis.
    Gao M; Zhang X
    Methods Mol Biol; 2008; 384():783-801. PubMed ID: 18392595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic approaches to biomarker discovery in prostate and bladder cancers.
    Adam BL; Vlahou A; Semmes OJ; Wright GL
    Proteomics; 2001 Oct; 1(10):1264-70. PubMed ID: 11721637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma.
    Wu TF; Ku WL; Tsay YG
    Expert Rev Proteomics; 2007 Oct; 4(5):639-47. PubMed ID: 17941819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5 kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.
    MacLennan MS; Kok MGM; Soliman L; So A; Hurtado-Coll A; Chen DDY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Feb; 1074-1075():79-85. PubMed ID: 29334632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies.
    Bernardino RMM; Leão R; Henrique R; Pinheiro LC; Kumar P; Suravajhala P; Beck HC; Carvalho AS; Matthiesen R
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.
    Theodorescu D; Wittke S; Ross MM; Walden M; Conaway M; Just I; Mischak H; Frierson HF
    Lancet Oncol; 2006 Mar; 7(3):230-40. PubMed ID: 16510332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies].
    Kovalev LI; Shishkin SS; Khasigov PZ; Dzeranov NK; Kazachenko AV; Toropygin IIu; Mamykina SV
    Prikl Biokhim Mikrobiol; 2006; 42(4):480-4. PubMed ID: 17022460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
    Wright GL
    Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
    Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
    Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MALDI mass spectrometry in prostate cancer biomarker discovery.
    Flatley B; Malone P; Cramer R
    Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.
    Stalmach A; Albalat A; Mullen W; Mischak H
    Electrophoresis; 2013 Jun; 34(11):1452-64. PubMed ID: 23512263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
    Latosinska A; Frantzi M; Vlahou A; Mischak H
    Proteomics Clin Appl; 2013 Dec; 7(11-12):779-93. PubMed ID: 23970371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery.
    Niu D; Feng H; Chen WN
    J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.